Florida Federal Court Enjoins Apotex from Selling Neulasta Biosimilar for 180 Days After Approval
By EsqSocial Corporation 14/12/15
On December 9, a federal district court in Florida issued a preliminary injunction prohibiting Apotex from selling a proposed biosimilar version of Amgen’s cancer drug Neulasta for 180 days after the biosimilar is approved. In the decision, the...
By: Patterson Belknap Webb & Tyler LLP